Key result
Fixed-dose atorvastatin/ezetimibe achieves bioequivalent systemic exposure compared to separate tablets.
Why the study?
Combination therapy with a statin and ezetimibe is recommended for patients with dyslipidemia not reaching LDL cholesterol targets on monotherapy. The pharmacokinetics and safety of a fixed-dose combination of atorvastatin/ezetimibe 5 mg/10 mg needed comparison against the separate individual components.
Does a fixed-dose combination tablet of atorvastatin/ezetimibe 5 mg/10 mg provide equivalent pharmacokinetic exposure and comparable safety to separate tablets of atorvastatin 5 mg and ezetimibe 10 mg in healthy Korean adults?
RCT (n=60)
Open-label
Randomized 1:1 to 2 sequences in a 2-treatment, 2-sequence crossover design
No
Does a fixed-dose combination tablet of atorvastatin/ezetimibe 5 mg/10 mg provide equivalent pharmacokinetic exposure and comparable safety to separate tablets of atorvastatin 5 mg and ezetimibe 10 mg in healthy Korean adults?
Answers are grounded in this paper and cite their sources.
The fixed-dose combination of atorvastatin/ezetimibe 5 mg/10 mg is well tolerated and demonstrates similar overall systemic exposure (AUClast) to separate component tablets, supporting its use to improve medication compliance in patients with dyslipidemia.
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors are well-established treatment options for dyslipidemia.For patients not meeting low-density lipoprotein cholesterol targets with monotherapy, combination therapy with another lipid-lowering agent including ezetimibe, is recommended.This study compared the pharmacokinetics (PKs) and safety of a fixed-dose combination (FDC) of atorvastatin/ezetimibe 5 mg/10 mg with the individual components in healthy Korean subjects.A randomized, open-label, single-dose, 2-treatment, 2-sequence, crossover study was conducted in 60 healthy subjects.An FDC of atorvastatin/ezetimibe 5 mg/10 mg or the corresponding individual components was administered in the first period, and the alternative in the second period after a 14day washout.Serial blood samples were collected up to 72 hours post-dose to calculate PK parameters such as maximum plasma concentration (C max ) and the area under the plasma concentration-time curve to the last measurable concentration (AUC last ).The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) of the C max and AUC last for the atorvastatin and total ezetimibe were estimated compared to the individual components.Adverse events (AEs) and other safety variables were monitored to evaluate safety and tolerability profile.Sixty subjects were enrolled and 58 subjects completed the study.For atorvastatin, the GMRs (90% CIs) for C max and AUC last were 1.18 (1.04-1.33)and 1.04 (1.00-1.08),respectively, and the corresponding values were 1.37 (1.26-1.50)and 0.98 (0.93-1.03) for total ezetimibe.No clinically significant treatment-emergent AEs were observed with either formulations.The FDC of atorvastatin/ezetimibe 5 mg/10 mg was safe and showed similar exposure to those of the individual components.
No takes yet. Share an insight, caveat, or question.
Bae et al. (2025) conducted an RCT in Healthy subjects (pharmacokinetic study for dyslipidemia therapy) (n=60). Atorvastatin/ezetimibe fixed-dose combination (FDC) vs. Separate tablets of atorvastatin 5 mg and ezetimibe 10 mg was evaluated on Area under the plasma concentration-time curve to the last measurable concentration (AUClast) for atorvastatin (GMR 1.04 (90% CI 1.00-1.08); total ezetimibe AUClast GMR 0.98 (90% CI 0.93-1.03)). Fixed-dose combination atorvastatin/ezetimibe / showed bioequivalent systemic exposure (AUClast) to separate tablets for atorvastatin and total ezetimibe.
Synapse has enriched 10 related papers. Consider them for comparative context: